MimiVax Announces Positive Final Data from the Phase IIa Study of SurVaxM for Newly Diagnosed Glioblastoma Published Today in the Journal of Clinical Oncology

/PRNewswire/ -- MimiVax is pleased to announce the published manuscript of the now completed Phase IIa study of SurVaxM, a cancer vaccine, in newly diagnosed...

Related Keywords

Miami ,Florida ,United States ,New York ,Cleveland Clinic ,Beth Israel Medical Center ,Texas ,Dana Farber Cancer Institute ,Massachusetts ,Michael Ciesielski ,Prnewswire Mimivax ,Manmeet Ahluwalia ,Roswell Park Comprehensive Cancer Center ,Baptist Health South Florida ,Beth Israel Deaconess Medical Center ,Fernandez Family Foundation ,Fred Hutchinson Cancer Center ,Cancer Research ,Miami Cancer Institute ,Norton Cancer Institute ,Roswell Park Alliance Foundation ,Clinical Oncology ,Massachusetts General ,Progression Free Survival ,Overall Survival ,Fernandez Family Foundation Endowed Chair ,Medical Oncology ,Deputy Director ,Chief Scientific Officer ,Baptist Health South ,Blinded Placebo Controlled Phase ,Overlook Medical Center ,Texas Oncology ,Chief Executive Officer ,Survaxm Plus Adjuvant Temozolomide ,Newly Diagnosed Glioblastoma ,Clin Oncol ,Roswell Park Alliance ,